oxaliplatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  

1710 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
FOLFIRINOX-R, NCT03828799: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

Active, not recruiting
1/2
13
Europe
Folfirinox + regorrafenib
Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer
12/21
11/24
IPLUS, NCT03618758: Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Completed
1/2
35
RoW
Paclitaxel, (Genexol®), mFOLFOX6 regimen
Seoul National University Bundang Hospital, Boryung Pharmaceutical Co., Ltd, B. Braun Korea Co., Ltd.
Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
08/23
12/23
NCT03991104: SOX-based CRT for Esophageal Cancer.

Withdrawn
1/2
45
RoW
Oxaliplatin, S-1 capsule, Intensity modulated radiotherapy (IMRT)
Zhejiang Provincial People's Hospital
Esophageal Cancer
12/21
12/23
ChiCTR2000032590: A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-Line Therapy for Patients with Metastatic Colorectal Cancer

Recruiting
1/2
106
 
XELOXIRI/bevacizumab
Department of Medical Oncology, National Center/Cancer Hospital, China Academy of Medical Science and Peking Union Medical College; Cancer Hospital, China Academy of Medical Science and Peking Union Medical College, No financial support
Metastatic Colorectal Cancer
 
 
HyRec, NCT01716949: Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer

Recruiting
1/2
59
Europe
Radiotherapy, Hyperthermia, 5-Fluorouracil, all brands of 5-Fluorouracil are allowed, Capecitabine, all brands of Capecitabine are allowed, Oxaliplatin, all brands of oxaliplatin are allowed
University of Erlangen-Nürnberg Medical School
Rectal Cancer
06/22
06/23
NCT04979663: GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Recruiting
1/2
10
RoW
Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Fudan University
Biliary Tract Carcinoma
06/22
06/22
NCT04228601: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Recruiting
1/2
66
RoW
Fluzoparib, SHR3162, Fluzoparib placebo, mFOLFIRINOX
Jiangsu HengRui Medicine Co., Ltd.
Advanced Pancreatic Cancer
08/22
02/23
TAXE-GC, NCT04963088: TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma

Recruiting
1/2
66
RoW
BGB-A317, Anlotinib, Oxaliplatin, Capecitabine
The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer
09/22
03/24
HLX07Ib/II, NCT03577704: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.

Completed
1/2
56
RoW
HLX07+Gemcitabine+Cisplatin, Recombinant anti-EGFR humanized monoclonal antibody, Gemzar, Cisplatin, HLX07+Paclitaxel+Carboplatin, Paclitaxel, Carboplatin, HLX07+mFOLFOX6, Oxaliplatin for Injection, Folinic acid calcium salt hydrate, 5-fluouracil
Shanghai Henlius Biotech
Advanced Solid Tumors
09/22
12/22
COLUMBIA 1, NCT04068610: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Terminated
1/2
61
Europe, Canada, US, RoW
Durvalumab, MEDI4736, Oleclumab, MEDI9447, FOLFOX, Bevacizumab
MedImmune LLC
Metastatic Microsatellite-stable Colorectal Cancer
10/22
10/22
NCT03761914: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Active, not recruiting
1/2
90
US
galinpepimut-S, SLS-001, GPS, WT1 Analog Peptide Vaccine, Pembrolizumab, MK-3475, Keytruda
Sellas Life Sciences Group, Merck Sharp & Dohme LLC, Cancer Insight, LLC
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
11/22
04/23
NCT05111860: Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Recruiting
1/2
20
RoW
Bevacizumab+mFOLFOX6
Shanghai Minimally Invasive Surgery Center
Neoadjuvant Treatment, Rectal Cancer, Bevacizumab, Radiotherapy
08/24
08/25
NCT04008511: Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Not yet recruiting
1/2
54
RoW
Regorafenib, Stivarga, Capecitabine, Xeloda, Oxaliplatin, ELOXATIN®
China Medical University, China, Liaoning Tumor Hospital & Institute, The First People's Hospital of Jingzhou
Metastatic Colorectal Cancer
03/23
03/24
AK117-204, NCT05235542: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Recruiting
1/2
130
RoW
AK104, AK117, Capecitabine tablets, Oxaliplatin, Cisplatin, Paclitaxel, Irinotecan, Docetaxel, 5-FU
Akeso
Advanced Malignant Tumors
03/23
03/24
NCT04911816: Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Recruiting
1/2
40
US
Hydroxychloroquine sulfate, Plaquenil
West Virginia University
Adenocarcinoma of the Pancreas
06/25
06/28
NCT05116891: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
1/2
40
Europe
CAN04 (nadunolimab), nadumolimab, mFOLFOX, Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin, DTX, Docetaxel, G/C, Gemcitabine and cisplatin
Cantargia AB
Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
06/23
06/23
SYS-CAPLIOX, NCT04701281: Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer

Recruiting
1/2
95
RoW
Intra-arterial LIOX + Capecitabine
AllVascular
Liver Metastasis Colon Cancer
07/23
07/23
PRECISE CURATE.AI, NCT04522284: Pilot Clinical Trial

Recruiting
1/2
20
RoW
CURATE.AI, Capecitabine, XELODA, XELOX, XELIRI, Ibrutinib
National University Hospital, Singapore, The N.1 Institute for Health (N.1)
Solid Tumor
08/23
08/23
NCT05024812: Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
1/2
64
RoW
fruquintinib＋toripalimab + SOX
The First Affiliated Hospital of Zhengzhou University
Metastatic Gastric Cancer
08/23
02/25
NCT05721872: Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer

Recruiting
1/2
38
RoW
D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO), FOLFOX/FOLFIRI regimen
Nazarbayev University, National Laboratory Astana
Colorectal Cancer, Metastatic Colorectal Cancer
08/23
11/23
NCT03633734: Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
49
RoW
Sequential Treatment, Sequential Treatment With AG and Modified Folfirinox
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect
08/23
12/24
COMPASSION-03, NCT03852251: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Active, not recruiting
1/2
338
RoW
AK104, Oxaliplatin, Capecitabine
Akeso, Akeso Pharmaceuticals, Inc.
Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
08/23
08/23
NCT04940546: Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients

Active, not recruiting
1/2
36
RoW
Sintilimab, Anti-PD-1 monoclonal antibody IBI308, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Bevacizumab, Avastin
Sun Yat-sen University
Colorectal Cancer Metastatic
10/23
10/24
NCT03699319: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Active, not recruiting
1/2
49
US
CPI 613, 6, 8-bis-benzylsulfanyloctanoic acid, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, 5-flurouracil, 5FU, Folinic acid, Leucovorin, Calcium folinate, FA
David Bajor
Pancreatic Cancer
09/24
09/24
NASOX, NCT04662112: Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma

Active, not recruiting
1/2
40
RoW
NASOX
Asan Medical Center, Hallym University Medical Center
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
10/23
12/24
NuTide:302, NCT03428958: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Completed
1/2
107
Europe, US
NUC-3373 + leucovorin, folinic acid, levoleucovorin, Nucleotide analogue, NUC-3373, NUFOX, Eloxatin, NUFOX + VEGF pathway inhibitor, Avastin, NUFOX + EGFR inhibitor, Erbitux, Vectibix, NUFIRI, Campto, Camptosar, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab
NuCana plc
Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
03/24
03/24
ChanghaiH-PP05, NCT04324307: Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
1/2
60
RoW
PD-L1/CTLA4 BsAb, GP, Gemcitabine, nab-Paclitaxel, FOLFIRINOX, Oxaliplatin, Irinotecan, Calcium Folate, Fluorouracil
Changhai Hospital
Locally Advanced and Metastatic Pancreatic Cancer
11/23
11/23
TWINPEAK, NCT05482893: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
114
US
PT886, Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/25
04/26
NCT06139211: A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Not yet recruiting
1/2
186
RoW
JS015, Toripalimab, Paclitaxel, Irinotecan, Capecitabine, Oxaliplatin, Bevacizumab, Fluorouracil, Leucovorin, Gemcitabine, Albumin-Bound Paclitaxel
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Advanced Solid Tumor
11/25
04/26
NCT04043195: Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Active, not recruiting
1/2
30
US
Nivolumab, Oxaliplatin, Ipilimumab
Hatim Husain
Advanced NSCLC
12/23
12/25
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed
1/2
29
Europe, US
MEN1611, Cetuximab
Menarini Group, Menarini Ricerche S.p.A.
Metastatic Colorectal Cancer
01/24
02/24
IPXELOX, NCT04943653: Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis

Recruiting
1/2
61
RoW
Paclitaxel, capecitabine, oxaliplatin
Seoul St. Mary's Hospital
Stomach Neoplasms, Paclitaxel, Peritoneal Metastases
12/23
12/25
BGB-A317-ZW25-101, NCT04276493: Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

Active, not recruiting
1/2
71
RoW
ZW25, Docetaxel, Tislelizumab, BGB-A317, Capecitabine, Oxaliplatin
BeiGene
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
12/23
12/26
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
08/24
11/24
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Hourglass Dec 2022 - Dec 2022 : First-patient-in of ARM-C of TOUCH trial in combination with tislelizumab for r/r/ peripheral T- and NK/T-cell lymphoma
Checkmark Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Nov 2022 - Nov 2022: Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Checkmark Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Dec 2021 - Dec 2021: Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Active, not recruiting
1/2
56
RoW
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
Antengene Corporation
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
12/24
12/24
NCT05608785: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Not yet recruiting
1/2
45
NA
IBI315, Oxaliplatin, Capecitabine, TST001, TQB2450, Anrotinib
Henan Cancer Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
12/23
10/24
SYLT-023, NCT05319639: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Recruiting
1/2
20
RoW
Oxaliplatin, Levo-Leucovorin, 5-fluorouracil, Paclitaxel, Irinotecan, Tislelizumab
Fujian Cancer Hospital
Gastric Cancer Stage IV
12/23
12/24
HERIZON, NCT02795988: A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Active, not recruiting
1/2
36
RoW
IMU-131, HER-Vaxx, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine., Standard of Care Chemotherapy
Imugene Limited
Gastrointestinal Neoplasms, Adenocarcinoma
03/24
08/24
NCT02826837: LEAC-102 for Advanced Colorectal Cancer

Not yet recruiting
1/2
30
NA
LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
Taiwan Leader Biotech Corp.
Advanced Colorectal Cancer
02/24
02/24
ONC001, NCT04393298: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Completed
1/2
95
Europe, US
ginisortamab, UCB6114, trifluridine/tipiracil, TAS-102, Lonsurf®, mFOLFOX6, Calcium folinate, 5-FU, fluorouracil
UCB Biopharma SRL
Advanced Solid Tumors
04/24
04/24
TASKIN, NCT05201352: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine

Recruiting
1/2
160
Europe
trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo
Centre Georges Francois Leclerc
Metastatic Colorectal Cancer
10/26
10/26
NCT05834231: Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity

Not yet recruiting
1/2
60
NA
Memantine, Placebo
Mansoura University
Cancer
03/24
10/24
NCT05198856: Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC

Not yet recruiting
1/2
106
NA
Thalidomide Combined With Chemotherapy and Monotherapy, Fanyingting
Qilu Hospital of Shandong University
Gastric Cancer Metastatic to Liver
03/24
12/24
NCT06266871: SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Not yet recruiting
1/2
64
NA
SOX+Tislelizumab+LDRT
West China Hospital
Gastric Cancer
06/26
07/26
NCT04807972 / 2020-005767-31: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Completed
1/2
40
Europe, US, RoW
ABBV-927, Budiglimab, ABBV-181, modified FOLFIRINOX, mFFX
AbbVie
Pancreatic Cancer
03/24
03/24
REGONIVOCTx, NCT05394740: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Active, not recruiting
1/2
30
Japan
Regorafenib, Stivarga, Nivolumab, Opdivo, CapeOX, XELOX, Capecitabine and Oxaliplatin, FOLFOX regimen, Leucovorin, Fluorouracil and Oxaliplatin
National Cancer Center Hospital East, Bayer Yakuhin, Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
05/24
11/25
OrigAMI-1, NCT05379595: A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Recruiting
1/2
225
Europe, Canada, US, RoW
Amivantamab, RYBREVANT, JNJ-61186372, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan
Janssen Research & Development, LLC
Advanced or Metastatic Colorectal Cancer
04/27
04/27
NCT05846867: Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients

Not yet recruiting
1/2
72
RoW
AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate, Fluorouracil
Akeso
Colorectal Cancer
05/24
07/25
NCT06445062: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting
1/2
406
US
RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel
Revolution Medicines, Inc.
Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
05/27
07/27
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
COMBATBIL, NCT05052099: Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer

Recruiting
1/2
35
Europe
mFOLFOX6, Atezolizumab and Bevacizumab
University Hospital, Essen
Biliary Tract Cancer
06/24
06/24
TransStar101, NCT04396821: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
150
US
TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Gemzar, Albumin-Bound Paclitaxel
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
06/24
12/24
NCT04821284: Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Recruiting
1/2
120
Europe, US
Gemcitabine Hydrochloride, 1-(2-Oxo-4-amino-1, 2-dihydropyrimidin-1-yl)-2-deoxy-2, 2-difluororibose, hydrochloride, 122111-03-9, 2'Deoxy-2', 2'-Difluorocytidine, Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, nanoparticle paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, protein-bound paclitaxel, Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 FU, 5 Fluorouracilum, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5-Fu, 51-21-8, 5FU, AccuSite, Carac, Fluoro Uracil, fluorouraci, Fluouracil, Flurablastin, Fluracedy, Fluracil, Fluril, Ribofluor, Ro 2-9757, Irinotecan Hydrochloride, 136572-09-3, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, 5-Formyl-5,6,7,8-tetrahydrofolic Acid, 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calcium N-(p-((((6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamate (1:1), Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, N-[4-[[(2-Amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amnio]benzoyl]-L-glutamic Acid, Calcium Salt (1:1), N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]glutamic Acid, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, 61825-94-3, [(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum, [SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N, N')[ethanedioato(2--)-O, O']platinum, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, oxalato (1R,2R-cyclohexanediamine)platinum(II), Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, trans-l DACH oxalatoplatinum, trans-l diaminocyclohexane oxalatoplatinum, Perflubutane Microbubble, Contrast-Enhanced Ultrasound, Quality-of-Life Assessment, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT SCAN, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging
Flemming Forsberg, National Cancer Institute (NCI)
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
12/24
01/25
PREOPANC-5, NCT06384560: Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer

Not yet recruiting
1/2
66
NA
Pembrolizumab, Folfirinox, SABR
Amsterdam UMC, location VUmc, Maastricht University Medical Center, Erasmus Medical Center, St. Antonius Hospital
Borderline Resectable Pancreatic Cancer
03/28
03/28
NCT06469944: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Not yet recruiting
1/2
130
NA
Pembrolizumab, MK-3475, Keytruda®, Sacituzumab Tirumotecan, MK-2870, SKB264, Capecitabine, XELODA, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, 5-FU, ADRUCIL®
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
01/27
04/29
NCT02953509 / 2016-003408-29: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Checkmark Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Jan 2023 - Jan 2023: Data from P1b trial in combination with rituximab for DLBCL at ASH 2022
Hourglass Apr 2020 - Sep 2020 : Safety and efficacy data from P1b trial in combination with rituximab for DLBCL
Checkmark In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
Jun 2019 - Jun 2019: In combination with rituximab in DLBCL and FL patents at EHA 2019 [screenshot]
More
Terminated
1/2
178
Europe, US, RoW
Magrolimab, Hu5F9-G4, Rituximab, RITUXAN®, MabThera, Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®
Gilead Sciences, The Leukemia and Lymphoma Society
Non Hodgkin Lymphoma
03/24
03/24
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
08/24
04/25
NCT05964543: The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors

Recruiting
1/2
72
RoW
Q-1802 Injection,Oxaliplatin Injection,Capecitabine, Q-1802,Oxaliplatin Injection,Xeloda
QureBio Ltd.
Gastroesophageal Junction (GEJ) Adenocarcinoma
08/24
08/25
NCT03868228: PIPAC for the Treatment of Colorectal Peritoneal Metastases

Recruiting
1/2
30
Europe
Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), CapnoPen
Imperial College London, Barts Cancer Institute
Colorectal Neoplasms, Peritoneal Metastases
09/24
09/24
NCT06041035: A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
115
RoW
QLS31905, Nab paclitaxel, Gemcitabine, Oxaliplatin, Capecitabine, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Solid Tumor
10/24
10/25
NCT05640609: Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Recruiting
1/2
57
RoW
Capeox regimen combined with Sintilimab and Bevacizumab
West China Hospital
Stomach Neoplasm
11/24
11/26
FOLFIRINOX3, NCT03795311: Evaluation of the Efficacy and the Safety of Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

Active, not recruiting
1/2
30
Europe
FOLFIRINOX Bevacizumab
Centre Georges Francois Leclerc
Colorectal Cancer
11/24
11/24
PanC-ASAP, NCT04431258: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Completed
1/2
150
Europe, US, RoW
ABTL0812, Folfirinox, Chemotherapy, Placebo
Ability Pharmaceuticals SL
Pancreatic Cancer
01/24
01/24
EPCORE NHL-3, NCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

Active, not recruiting
1/2
102
Japan
epcoritamab (monotherapy), GEN3013, DuoBody®-CD3xCD20, EPKINLY™, epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, gemcitabine and oxaliplatin, Gemox, epcoritamab (maintenance), rituximab and lenalidomide, R2
Genmab, AbbVie
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
12/24
12/24
NCT05251948: An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Active, not recruiting
1/2
40
RoW
Atezolizumab, Tecentriq, Capecitabine, Oxaliplatin, Tiragolumab
Hoffmann-La Roche
Gastric and Gastroesophageal Junction Carcinoma
12/24
12/25
ChiCTR2200061306: The efficacy and safety of smart combined with PD-1 antibody and chemotherapy compared with PD-1 antibody combined with chemotherapy in the first-line treatment of locally advanced unresectable or metastatic, HER2 negative gastric / gastroesophageal junction adenocarcinoma (GEJ)

Recruiting
1/2
140
 
Escalating-dose of SmarT+PD-1 mAb+low dose radiotherapy ;Recommended dose of SmarT+PD-1mAb+oxaliplatin+S-1+low dose radiotherapy ;PD-1mAb+oxaliplatin+S-1
Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University; Nanjing Drum Tower Hospital, self-financing
adenocarcinoma of esophagogastric junction
 
 
NCT06409637: FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

Not yet recruiting
1/2
62
RoW
FOLFOX4 regimen, Oxaliplatin, Leucovorin, 5-Fluorouracil, lenvatinib, lenvatinib pill
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Liver Cancer, Liver Transplant
12/27
12/29
NCT03599778: XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Not yet recruiting
1/2
52
RoW
Apatinib, XELOX
Anhui Provincial Hospital
Gastric Carcinoma
01/25
01/25
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/25
04/25
NCT05632939: ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

Recruiting
1/2
57
RoW
ASKB589 +CAPOX+Sintilimab
AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Gastric Cancer
02/25
02/26
NCT05627635: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Recruiting
1/2
86
US
Balstilimab, AGEN 2034, AGEN-2034, AGEN2034, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Botensilimab, AGEN 1181, AGEN-1181, AGEN1181, Anti-CTLA-4 Monoclonal Antibody AGEN1181, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Radiographic Imaging, Radiography, RG, Static X-Ray, X-Ray
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
04/25
04/25
NCT05688215: Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Suspended
1/2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Core Biopsy, BIOPSY, CORE, CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quemliclustat, AB 680, AB-680, AB680, CD73 Inhibitor AB680, Zimberelimab, AB 122, AB-122, AB122, Anti-PD-1 Monoclonal Antibody GLS-010, GLS 010, GLS-010, GLS010, WBP-3055
Jonsson Comprehensive Cancer Center, Arcus Biosciences, Inc.
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
05/25
05/26
JSFOL, NCT03985891: The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer

Recruiting
1/2
40
RoW
Anti-PD-1 Monoclonal Antibody JS001, Toripalimab, Chemotherapy, Folfox
Xiangya Hospital of Central South University
Colonic Neoplasms, Chemotherapy Effect
06/25
06/26
MEFOX, NCT05212012: D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer

Recruiting
1/2
18
Europe
Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)
AIO-Studien-gGmbH, Deutsche Krebshilfe e.V., Bonn (Germany)
Chemo-refractory Colorectal Carcinoma
06/25
06/25
NCT06033118: Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Not yet recruiting
1/2
25
NA
gemcitabine ,oxaliplatin,anlotinib,Sintilimab
Sichuan University
Combined Hepatocellular Cholangiocarcinoma
07/25
08/26
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Active, not recruiting
1/2
340
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
10/25
10/26
NCT06047379: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Recruiting
1/2
134
US
NEO212 Oral Capsule, POH-TMZ, Ipilimumab, Yervoy, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Regorafenib, Stivagra, Carboplatin, Paraplatin, Paclitaxel, Taxol, FOLFIRI Protocol, Zaltrap, Bevacizumab, Avastin, Mvasi, Zirabev, Alymsys, Vegzelma
Neonc Technologies, Inc.
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
02/26
08/26
NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
NCT05926206: Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

Withdrawn
1/2
60
US
Devimistat, Modified FOLFIRINOX
University of Michigan Rogel Cancer Center
Metastatic Pancreatic Adenocarcinoma
01/27
01/27
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Hourglass Jan 2019 - Jan 2019 : P1/2 trial in advanced rectal cancer
Recruiting
1/2
39
US
Epacadostat, INCB024360, Short-course radiation, CAPOX chemotherapy
Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI)
Rectal Cancer
07/27
08/30
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29
NCT06069778: Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Recruiting
1/2
320
US
BNT321 Dose Level 1, BNT321 Dose Level 2, mFOLFIRINOX, BNT321 RP2D
BioNTech SE
Pancreatic Cancer
04/29
06/31
NCT05849480: A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting
1/2
60
US
oxaliplatin, capecitabine, Keytruda, CDX-1140
National Cancer Institute (NCI)
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
06/40
06/42
Ni-HIGH, UMIN000034222: A phase Ib study of Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2 positive advanced gastric cancer

Active, not recruiting
1b
45
Japan
Opdivo (nivolumab) - Ono Pharma, BMS, capecitabine - Generic mfg., oxaliplatin - Generic mfg., Herceptin (trastuzumab) - Roche
The Cancer Institute Hospital of JFCR, Ono Pharmaceutical Co., Ltd.
HER2 positive advanced or unresectable gastric cancer
 
 
KEYNOTE-651, NCT03374254: Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)

Checkmark Initial data from KEYNOTE-651 combination trial with Mektovi in metastatic CRC
Sep 2019 - Sep 2019: Initial data from KEYNOTE-651 combination trial with Mektovi in metastatic CRC
Completed
1b
114
Canada, US
Pembrolizumab, MK-3475, Binimetinib, MEK162, ARRY-162, ARRY-438162, Oxaliplatin, Leucovorin, calcium folinate, 5-Fluorouracil [5-FU], Irinotecan
Merck Sharp & Dohme LLC, Array BioPharma
Metastatic Colorectal Cancer
09/21
07/23
CAPAFOUR, NCT04990037: A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Completed
1b
25
Europe
CAN04, Nadunolimab, FOLFIRINOX
Cantargia AB
Metastatic Pancreatic Ductal Adenocarcinoma
05/23
06/23
COSMIC-021, NCT03170960: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Checkmark Presentation of data from COSMIC-021 trial in combination with atezolizumab for HNSCC at SITC 2022
Dec 2021 - Nov 2022: Presentation of data from COSMIC-021 trial in combination with atezolizumab for HNSCC at SITC 2022
Checkmark Data from additional cohorts in combination with Tecentriq for solid tumors
Jul 2022 - Jul 2022: Data from additional cohorts in combination with Tecentriq for solid tumors
Checkmark P1b results in combination with Tecentriq for metastatic NSCLC at ASCO 2022 based on COSMIC-021 trial
More
Active, not recruiting
1b
1732
Europe, US, RoW
cabozantinib, Cabometyx, XL184, atezolizumab, Tecentriq
Exelixis
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
07/23
08/24
PROMIFOX, NCT04729205: Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

Terminated
1b
9
RoW
Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug, Folfox
Lipomedix Pharmaceuticals Inc.
Cancer, Gastro-Intestinal Intraepithelial Neoplasia
09/23
09/23
NCT04725994: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

Recruiting
1b
100
US, RoW
IDX-1197+XELOX, IDX-1197+Irinotecan
Idience Co., Ltd.
Gastric Cancer
09/23
03/24
ACTRN12624000455561: Safety and efficacy of faecal transplant and chemotherapy in the management of pancreatic cancer

Not yet recruiting
1
60
 
Central Adelaide Local Health Network (CALHN), Department of Health and Aged Care - Medical Research Future Fund (MRFF)
non-resectable pancreatic cancer
 
 
ACTRN12619000192189: Cimetidine for Reducing Oxaliplatin Neurotoxicity (CITRON)

Recruiting
1
60
 
University of Auckland, Health Research council
Colorectal cancer, Gastrointestinal cancer
 
 
NCT00873275: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Active, not recruiting
1
11
US
bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
City of Hope Medical Center, National Cancer Institute (NCI)
Colorectal Cancer
09/12
01/25
ChiCTR-ONRC-13004023: Phase I Clinical Trial of 7-Day Capecitabine in Combination with Docetaxel and Oxaliplatin in the Treatment of Advanced Malignant Solid Tumors

Completed
1
12
 
docetaxel 75 mg/m2, d1; q21d+oxaliplatin100mg/m2, d1; q21d+capecitabine1000mg/m2, bid, d1-7; q21d ;docetaxel 75 mg/m2, d1; q21d+oxaliplatin120mg/m2, d1; q21d+capecitabine1000mg/m2, bid, d1-7; q21d ;docetaxel 75 mg/m2, d1; q21doxaliplatin100mg/m2, d1; q21d+oxaliplatin100mg/m2, d1; q21d+capecitabine1250mg/m2, bid, d1-7; q21d
Affiliated Cancer Hospital of Guangxi Medical University/Cancer Hospital of Guangxi Zhuang Autonomous Region; Affiliated Cancer Hospital of Guangxi Medical University, Guangxi nature science fund; Guangxi health care key scientific research project; Guangxi self-financing scientific research project
Advanced malignant solid tumor
 
 
NCT01835041: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Completed
1
21
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
02/17
03/23
ChiCTR-TRC-08000122: Randomized controlled study on preoperative chemoradiation assisted radical operation for mid-low rectal carcinoma

Recruiting
1
400
 
1. Routine preoperative radiotherapy (2 Gy once a day, 5 times/ week, for total 46 Gy) + concurrent chemotherapy (mXelox) + total mesorectum excision; 2. Postoperative chemotherapy: Xelox. ;Total mesorectum excision; postoperative chemotherapy: Xelox
Sun Yat-sen University; Level of the institution：, Clinical Trials Program of Sun Yat-sen University (“5010” Program)
Rectal carcinoma
 
 
NCT03279237: A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Active, not recruiting
1
25
US
Irinotecan, Camptosar, Oxaliplatin, Eloxatin, Leucovorin, 5-Fluorouracil, Efudex, Paclitaxel, Abraxane, Radiation Therapy, Carboplatin
Massachusetts General Hospital, National Cancer Institute (NCI)
GastroEsophageal Cancer
11/18
09/23
NCT02009449: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Checkmark In combination with pembrolizumab/ nivolumab for advanced RCC
Sep 2019 - Sep 2019: In combination with pembrolizumab/ nivolumab for advanced RCC
Checkmark Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: Additional data from P1/1b trial in combination with FOLFOX for PDAC at ESMO 2017 [screenshot]
Checkmark From AM0010/AM0010 + anti-PD-1 in NSCLC at ESMO 2017 [screenshot]
More
Active, not recruiting
1
350
US
Pegilodecakin, LY3500518, AM0010, PEGylated recombinant human Interleukin-10, PEG-rHuIL-10, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, Taxol or taxotere and paraplatin or platinol, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), Eloxatin®/Leucovorin/5-FU, gemcitabine/nab-paclitaxel, Gemzar/Abraxane ABI-007, Capecitabine, Xeloda, Pazopanib, GW786034, Pembrolizumab, Keytruda, MK-3475, Paclitaxel, nivolumab, Keytruda, Gemcitabine/carboplatin, gemzar/paraplatin
Eli Lilly and Company, ARMO BioSciences
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
02/19
08/24
NCT05888675: Clinical Study of Weifuchun Treatment on Gastric Cancer

Completed
1
72
NA
Weifuchun
ShuGuang Hospital
Gastric Cancer (Diagnosis)
10/20
10/20
NIPOX, NCT03253133: Assessing Safety of in Peritoneal Carcinomatosis of CRC

Completed
1
19
Europe
Oxaliplatin, LV5FU or Folfiri, Oxycodone
Institut du Cancer de Montpellier - Val d'Aurelle
Colorectal Cancer
10/20
04/23
NCT02435927: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

Checkmark Pooled analysis from three studies at ASCO GI 2019 [screenshot]
Jan 2019 - Jan 2019: Pooled analysis from three studies at ASCO GI 2019 [screenshot]
Active, not recruiting
1
60
RoW
ASLAN001+ CAPOX (Oxaliplatin, capecitabine), eloxatin, xeloda, ASLAN001 + mFolfox6 (5-FU, leucovorin), 5-Fluorouracil, Folinic acid
National Cancer Centre, Singapore, Aslan Pharmaceuticals, National Medical Research Council (NMRC), Singapore
Solid Tumors
06/21
06/21
 

Download Options